(R)-3-Hydroxybutanoate

(R)-3-Hydroxybutanoate

SCHEMBL7765391

C[C@H](O)CC(=O)[O-].[Na+]

nearest known ligand 0.00

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ABCC8ACEADORA1ADORA2AADORA2BADORA3ALDH5A1ALOX5ALOX5APATP4AATP4BBRAFCA1CA12CA2CA4CYSLTR1DHFRDPEP1EDNRAEDNRBESR2F10FDPSFGF1GABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGARTGNRHRGSC1HMGCRIMPDH1IMPDH2KCNJ11LY96NOD2NR3C1NS3NS4ANS5bP2RY1P2RY12P2RY2P2RY4P2RY6PBP2XPDE3APDE3BPDE4APDE4BPDE4CPDE4DPDK1PDK2PDK3PDK4PPARGPPATPTGIRPTGS1PTGS2RAF1RYR1RYR3SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASERPINC1SLC12A1SLC12A3SYKTHRATHRBTLR3TLR4TLR9TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYMSVKORC1XDHblablaIMP-1blaOXA-33blaOXA-58blaT-3blaT-4blaT-5blaT-6dacAdacBdacCfolAfolPfolP1ftsIfusAgaggyrAgyrBmecAmrcAmrcBmrdApbp1apbp1bpbp2pbp2apbp2bpbp3pbp4pbpApbpBpbpCpbpFpolponBrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpoArpoBrpoCrpoZrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO

The experimentally established mechanism targets of (R)-3-Hydroxybutanoate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-110248652-B 3-hydroxybutyric acid alone or in combination for intensive care therapy 鲁汶大学 2023-05-26 CN claimed
EP-3923925-A1 RACEMIC BETA-HYDROXYBUTYRATE MIXED SALT-ACID COMPOSITIONS AND METHODS OF USE Axcess Global Sciences, LLC (US) 2021-12-22 EP claimed
US-20210177786-A1 RACEMIC AND NEAR RACEMIC BETA-HYDROXYBUTYRATE MIXED SALT-ACID COMPOSITIONS AXCESS GLOBAL SCIENCES, LLC 2021-06-17 US claimed
US-10973792-B2 Racemic beta-hydroxybutyrate mixed salt-acid compositions and methods of use AXCESS GLOBAL SCIENCES, LLC (US) 2021-04-13 US claimed
WO-2020167690-A1 RACEMIC BETA-HYDROXYBUTYRATE MIXED SALT-ACID COMPOSITIONS AND METHODS OF USE ACCESS GLOBAL SCIENCES, LLC (US) 2020-08-20 WO claimed
US-20200253909-A1 RACEMIC BETA-HYDROXYBUTYRATE MIXED SALT-ACID COMPOSITIONS AND METHODS OF USE AXCESS GLOBAL SCIENCES, LLC 2020-08-13 US claimed
CN-110248652-A 3-hydroxybutyrate is used singly or in combination to treatment intensive care 鲁汶大学 2019-09-17 CN claimed
US-12409159-B2 3-hydroxybutyrate alone or in combination for use in the treatment of critical care treatment KATHOLIEKE UNIVERSITEIT LEUVEN (BE) 2025-09-09 US disclosed
US-20230310353-A1 3-HYDROXYBUTYRATE ALONE OR IN COMBINATION FOR USE IN THE TREATMENT OF CRITICAL CARE TREATMENT KATHOLIEKE UNIVERSITEIT LEUVEN (BE) 2023-10-05 US disclosed
CN-110248652-B 3-hydroxybutyric acid alone or in combination for intensive care therapy 鲁汶大学 2023-05-26 CN disclosed
EP-2914563-B1 PRINTING PROCESS WZR CERAM SOLUTIONS GMBH (DE) 2021-06-30 EP disclosed
CN-110248652-A 3-hydroxybutyrate is used singly or in combination to treatment intensive care 鲁汶大学 2019-09-17 CN disclosed
EP-2914563-A1 PRESSURE PROCESS WZR Ceramic Solutions GmbH (DE) 2015-09-09 EP disclosed
WO-2014067990-A1 PRESSURE PROCESS WZR ceramic solutions GmbH (DE) 2014-05-08 WO disclosed
CN-101974603-A Method for producing D-alpha-hydroxybutyric acid UNIV SHANDONG 2011-02-16 CN disclosed
EP-1105416-A1 NOVEL PROCESS FOR THE SYNTHESIS OF EXOCHELINS Keystone Biomedical, Inc. (US) 2001-06-13 EP disclosed
US-6063919-A ESTERIFICATION OF O-DEPROTECTED DIBENZYL EXOCHELIC ACID WITH BENZYL EPI-COBACTIN, HYDROGENOLYTICALLY REMOVING THE THREE BENZYL GROUPS TO FORM EXOCHELIN 786SM(R) KEYSTONE BIOMEDICAL, INC. (US) 2000-05-16 US disclosed
WO-2000009547-A1 NOVEL PROCESS FOR THE SYNTHESIS OF EXOCHELINS KEYSTONE BIOMEDICAL, INC. (US) 2000-02-24 WO disclosed